Kronos Bio Inc. (KRON)
0.98
0.00 (0.00%)
At close: Jan 15, 2025, 10:56 AM
undefined% (undefined)
| Bid | 0.98 |
| Market Cap | 59.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.43 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.99 |
| Volume | 8,987 |
| Avg. Volume (20D) | 271,411 |
| Open | 0.95 |
| Previous Close | 0.98 |
| Day's Range | 0.95 - 0.98 |
| 52-Week Range | 0.69 - 1.60 |
| Beta | undefined |
About KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The comp...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 58
Stock Exchange NASDAQ
Ticker Symbol KRON
Website https://kronosbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for KRON stock is "Hold." The 12-month stock price forecast is $1.62, which is an increase of 65.31% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
Kronos Bio Inc. is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of $2.10M, reflecting a -8.14% YoY shrinking and earnings per share of -0.3, making a -30.23% decrease YoY.
Analysts project revenue of $2.10M, reflecting a -8.14% YoY shrinking and earnings per share of -0.3, making a -30.23% decrease YoY.
